Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.

Abstract: The invention provides polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a human secreted crossveinless-homolog polypeptide. Other aspects of the invention include vectors containing processes for producing human secreted crossveinless-homolog polypeptides, and antibodies specific for such polypeptides.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human C-type lectin receptor-like proteins. Other aspects of the invention include vectors containing processes for producing novel human C-type lectin receptor-like polypeptides, methods for detecting novel human C-type lectin receptor-like polynucleotides, and nucleic acid arrays comprising the novel human C-type lectin receptor-like polynucleotides.